Data will unlock clinical and economic value in Europe’s challenging landscape
Launching a new drug has always been fraught with risks, and the pandemic raised the stakes. Emerging and mid-sized companies launching products in Europe are also navigating a healthcare ecosystem that is complex and fragile due to regulatory and cost pressures. With no margin for error, teams will need to rethink their data strategy to quickly unlock clinical and economic value.
